55 completed. 55 Phase 2, 14 Phase 1, 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 55 | Completed 55 |
| Phase 1 | 14 | Completed 14 |
| Phase 3 | 4 | Completed 4 |
Follow Hydroxychloroquine: new trials by email Literature Review of Hydroxychloroquine trials Research Report on Hydroxychloroquine
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Baricitinib in Sjogren's Syndrome Baricitinib, Hydroxychloroquine - Sjogren's Syndrome | Phase 2 | Completed | Peking Union Medical College Hospital | 87 | 2022-07-14 | 2026-03-11 |
| To Evaluate Maximally Tolerated Dose (MTD), Safety and Efficacy of CPI-613® (Devimistat) Plus Hydroxychloroquine in Patients With Relapsed or Refractory Clear Cell Sarcoma of Soft Tissue CPI-613 + Hydroxychloroquine - Sarcoma, Clear Cell | Phase 1 / Phase 2 | Completed | Cornerstone Pharmaceuticals | 16 | 2021-09-01 | 2023-05-24 |
| Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS Mutant Non-Small Cell Lung Cancer Binimetinib Pill, Hydroxychloroquine Pill - Non-Small Cell Lung Cancer, KRAS Mutation-Related Tumors | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 9 | 2021-04-09 | 2025-04-01 |
| Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Hydroxychloroquine as Treatment in Untreated Pancreas Cancer Paclitaxel protein bound, Gemcitabine, Cisplatin - Untreated Resectable Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Adenocarcinoma | Phase 2 | Completed | HonorHealth Research Institute | 19 | 2020-12-01 | 2026-07-21 |
| Paricalcitol and Hydroxychloroquine in Combination With Gemcitabine and Nab-Paclitaxel for Advanced Pancreatic Cancer Gemcitabine, Hydroxychloroquine, Nab-paclitaxel - Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma | Phase 2 | Completed | Emory University | 10 | 2020-09-14 | 2026-01-23 |
| Favipiravir vs Hydroxychloroquine vs Control in COVID -19 Hydroxychloroquine, Favipiravir, Routine care for COVID-19 patients - SARS-CoV 2, COVID-19 | Phase 2 | Completed | Royal College of Surgeons in Ireland - Medical University of Bahrain | 150 | 2020-08-11 | 2021-10-26 |
| A Study of Quintuple Therapy to Treat COVID-19 Infection Hydroxychloroquine, Azithromycin, Vitamin C - COVID-19, Corona Virus Infection | Phase 2 | Completed | ProgenaBiome | 118 | 2020-06-22 | 2024-02-29 |
| A Study of Hydroxychloroquine, Vitamin C, Vitamin D, and Zinc for the Prevention of COVID-19 Infection Hydroxychloroquine, Vitamin C, Vitamin D - COVID-19, Coronavirus Infection | Phase 2 | Completed | ProgenaBiome | 254 | 2020-06-22 | 2025-06-05 |
| LY3214996 +/- HCQ in Pancreatic Cancer Hydroxychloroquine Sulfate, LY3214996 - Pancreatic Cancer, Advanced Cancer | Phase 2 | Completed | Kimberly Perez, MD | 52 | 2020-05-27 | 2025-02-12 |
| Hydroxychloroquine as Chemoprevention for COVID-19 for High Risk Healthcare Workers Hydroxychloroquine Sulfate (HCQ) - Covid19 | Phase 2 | Completed | Hackensack Meridian Health | 48 | 2020-04-14 | 2021-05-12 |
| The Fleming [FMTVDM] Directed CoVid-19 Treatment Protocol Hydroxychloroquine, Azithromycin, Hydroxychloroquine, Doxycycline, Hydroxychloroquine, Clindamycin - CoVid 19 Positive | Phase 2 / Phase 3 | Completed | The Camelot Foundation | 1800 | 2020-04-11 | 2020-11-12 |
| An Investigation Into Beneficial Effects of Interferon Beta 1a, Compared to Interferon Beta 1b And The Base Therapeutic Regiment in Moderate to Severe COVID-19: A Randomized Clinical Trial Hydroxychloroquine, Lopinavir / Ritonavir, Interferon Beta-1A - COVID-19 | Phase 2 | Completed | Shahid Beheshti University of Medical Sciences | 60 | 2020-04-09 | 2020-05-05 |
| Double Therapy With IFN-beta 1b and Hydroxychloroquine Interferon Beta-1B, Hydroxychloroquine - COVID | Phase 2 | Completed | The University of Hong Kong | 60 | 2020-04-09 | 2020-07-28 |
| A Study of the Effectiveness of an Off Label Mefloquine Use for the Treatment of Patients With COVID19 Mefloquine, Hydroxychloroquine, Mefloquine + azithromycin + / - tocilizumab - Pneumonia, Viral, Respiratory Failure | Phase 2 / Phase 3 | Completed | Burnasyan Federal Medical Biophysical Center | 320 | 2020-04-08 | 2021-01-27 |
| University of Utah COVID-19 Hydrochloroquine Trial Hydroxychloroquine, Placebo oral tablet - Coronavirus Infection, Coronavirus | Phase 2 | Completed | University of Utah | 368 | 2020-04-04 | 2023-02-15 |
| Hydroxychloroquine in the Prevention of COVID-19 Infection in Healthcare Workers Hydroxychloroquine - COVID-19 | Phase 2 | Completed | Baylor Research Institute | 221 | 2020-04-03 | 2021-08-20 |
| COVID-19 PrEP HCW HCQ Study Hydroxychloroquine (HCQ) - COVID-19 | Phase 2 | Completed | NYU Langone Health | 130 | 2020-04-03 | 2022-12-14 |
| Hydroxychloroquine for COVID-19 Post-exposure Prophylaxis (PEP) Hydroxychloroquine Sulfate, Ascorbic Acid - COVID-19, Corona Virus Infection | Phase 2 / Phase 3 | Completed | University of Washington | 943 | 2020-03-31 | 2021-12-16 |
| Hydroxychloroquine vs. Azithromycin for Hospitalized Patients With Suspected or Confirmed COVID-19 Hydroxychloroquine, Azithromycin - COVID-19 | Phase 2 | Completed | Intermountain Health Care, Inc. | 85 | 2020-03-30 | 2022-04-20 |
| Efficacay of Chloroquine or Hydroxychloroquine in COVID-19 Treatment Chloroquine or Hydroxychloroquine - COVID-19, Coronavirus Infection | Phase 2 / Phase 3 | Completed | Tanta University | 194 | 2020-03-23 | 2021-08-02 |
Showing 20 of 55. Sign in to see all of them.
COVID-19 (12) · Pancreatic Neoplasms (6) · Coronavirus Infections (5) · Prostatic Neoplasms (3) · Adenocarcinoma (2) · Carcinoma, Non-Small-Cell Lung (2) · Colonic Neoplasms (2) · Colorectal Neoplasms (2) · Glioblastoma (2) · Lupus Erythematosus, Systemic (2) · Rectal Neoplasms (2) · Sjogren's Syndrome (2) · Atherosclerosis (1) · Autoimmune Diseases (1) · Carcinoma, Renal Cell (1)
Abramson Cancer Center at Penn Medicine (5) · Rutgers, The State University of New Jersey (3) · NYU Langone Health (2) · ProgenaBiome (2) · The University of Texas Health Science Center at San Antonio (2) · Amer Zureikat (1) · Baylor Research Institute (1) · Burnasyan Federal Medical Biophysical Center (1) · Cairo University (1) · Cornerstone Pharmaceuticals (1) · Dana-Farber Cancer Institute (1) · Elena Gonzalez Brant, MD (1) · Emory University (1) · Hackensack Meridian Health (1) · HonorHealth Research Institute (1)
United States (40) · Canada (3) · China (2) · United Kingdom (2) · Australia (1) · Bahrain (1) · Egypt (1) · Hong Kong (1) · Iran (1) · Russia (1) · Thailand (1)
Herbert Zeh, MD (2) · Sabine Hazan, MD (2) · Sukeshi Patel Arora, MD (2) · Adam Spivak, MD (1) · Anthony Joshua, MBBS(Hons) PhD (1) · Ashutosh M. Shukla, MD MBBS (1) · Betul Hatipoglu, MD (1) · Biren Saraiya, MD (1) · Brian Wolpin, MD, MPH (1) · Charu Aggarwal, MD (1) · David R Karp, MD PhD (1) · Debasish Tripathy (1) · Elena M Gonzalez Brant, MD (1) · Erkut Borazanci, MD (1) · H. Michael Belmont, MD (1)
PMID 29929491, PMID 22985607, PMID 24821822, PMID 24991840, PMID 28420720, PMID 30922594, PMID 31120501, PMID 31428515, PMID 32425051, PMID 32493468, PMID 32493478, PMID 32674792, PMID 32681228, PMID 32907357, PMID 33166179, PMID 33284679, PMID 33410109, PMID 33416261, PMID 33850184, PMID 34897194, PMID 35156519, PMID 35322077, PMID 35561317, PMID 35739299, PMID 36214614, PMID 36793118, PMID 36875717, PMID 37186063, PMID 38157653, PMID 38299639, PMID 39730001, PMID 39865083, PMID 40955637
P30CA072720 (3), 2008 (1), P30CA138292 (1), U01AR071077 (1), U01CA062475 (1)